CDK1 and colorectal carcinoma: In addition, Zhang et al. [39] indicated that frequent overexpression of CDK1 in human CRCs is associated with the therapeutic target, and the therapeutic resistance of BRAF mutant human CRC can be suppressed by targeting CDK1.